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Currently, there are no valid pre-operatively established biomarkers or algorithms that can accurately 
predict surgical and clinical outcome for patients with advanced epithelial ovarian cancer (EOC). 
In this study, we suggest that profiling of tumour parameters such as bioelectrical-potential and 
metabolites, detectable by electronic sensors, could facilitate the future development of devices to 
better monitor disease and predict surgical and treatment outcomes. Biopotential was recorded, using 
a potentiometric measurement system, in ex vivo paired non-cancerous and cancerous omental tissues 
from advanced stage EOC (n = 36), and lysates collected for metabolite measurement by microdialysis. 
Consistently different biopotential values were detected in cancerous tissue versus non-cancerous 
tissue across all cases (p < 0.001). High tumour biopotential levels correlated with advanced tumour 
stage (p = 0.048) and tumour load, and negatively correlated with stroma. Within our EOC cohort and 
specifically the high-grade serous subtype, low biopotential levels associated with poorer progression-
free survival (p = 0.0179, p = 0.0143 respectively). Changes in biopotential levels significantly correlated 
with common apoptosis related pathways. Lactate and glucose levels measured in paired tissues 
showed significantly higher lactate/glucose ratio in tissues with low biopotential (p < 0.01, n = 12). 
Our study proposes the feasibility of biopotential and metabolite monitoring as a biomarker modality 
profiling EOC to predict surgical and clinical outcomes.
Epithelial ovarian cancer (EOC) is a heterogeneous disease with a high risk of relapse and development of plat-
inum resistance conferring a poor prognosis1. The cornerstone of treatment is maximal-effort surgical cytore-
duction combined with a cytotoxic and targeted systemic approach2. In recent years, ultra-radical surgery has 
increasingly become more commonplace with multivisceral resection techniques reaching beyond standard sur-
gery and extending beyond the pelvis and even the abdomen to the thoracic cavity3. This ultra-radical approach 
requires not only a high institutional effort overall and highly specialized surgical expertise, but also maximal 
patient physical resources. However, despite a maximal effort approach, outcomes vary broadly with 20% of 
patients experiencing an early relapse with a less favourable outcome despite their initial tumour-free surgery4. 
With the morbidity and mortality of ultra-radical procedures being on average as high as 20% and 1–3% respec-
tively2, the National Institute for Health and Care Excellence (NICE) UK in 2013 published interventional pro-
cedure guidance about the use and value of ultra-radical surgery for advanced ovarian cancer and recommended 
its application only in carefully selected patients in an effort to reduce unnecessary iatrogenic morbidity5. To 
date, there are no valid pre-operatively established algorithms or biomarkers that can reliably inform on surgical 
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and clinical outcome in order to adapt the extent and radicality of treatment to each patient’s needs and tumour 
biology.
In an attempt to profile patient tumour biology and predict patient clinical outcome and surgical success, 
we exploited the basic property of every cell to develop electrical biopotential across its membrane due to the 
presence of different ion concentrations between the intracellular and extracellular space. Interestingly, a cell’s 
behaviour is controlled not only by its own resting potential but also by the potential of its neighbouring cells6. 
Moreover, the role of endogenous voltage potentials and bioelectric gradients in the dysregulation of cell inter-
actions leading to cancer has been highlighted recently7,8. Furthermore, ion channels have been suggested to be 
involved in cancer development and progression, from the initial proliferation process to metastasis, and in par-
ticular in multidrug resistance, which is associated with the treatment of ovarian cancer9. It has been shown that 
cancerous cells produce a different bioelectrical potential across the cell membrane than normal cells in different 
cancer types, including breast cancer10–13.
With the help of newly developed methodology14,15, we established a feasibility study to determine the practi-
cality of using biopotential as a predictive biomarker of surgical and clinical outcome after radical cytoreductive 
surgery for advanced primary or relapsed EOC. Our method enables the measurement of potential differences 
between paired macroscopically healthy and cancerous tissue samples by means of a combination of a Ag|AgCl 
electrode, a tungsten electrode and interfacing electronics, which allows for the recording of the biopotential pres-
ent between the Ag|AgCl electrode and the tissue sample pierced by the tip of the tungsten electrode. Figure 1a 
illustrates the experimental laboratory setup used for the tissue biopotential measurements while the method 
itself and its constituent components are detailed in Fig. 1b.
We measured biopotential in a cohort of ex vivo paired cancerous and non-cancerous omentum tissues 
excised during radical debulking surgeries for advanced EOC, and report associations between biopotential and 
tumour stage, and patient progression-free survival. As cancer cell metabolism is known to be anaerobic, in some 
paired samples in addition to monitoring biopotential, we also monitored tissue metabolism using microdialysis 
sampling and online measurement of glucose and lactate using biosensors16,17. Our overall objective is to generate 
a usable, validated biopotential and metabolic signature that could be applied at the onset of treatment efforts 
to predict clinical outcome in terms of early relapse and onset of platinum resistant disease and fulfil the highly 
unmet need of personalisation of surgical treatment in advanced ovarian cancer.
Results
Biopotential can be consistently measured in ex vivo tissue and differs between cancerous and 
non-cancerous omentum tissue. We developed a measurement system14 to facilitate reliable stable detec-
tion of resting biopotential in ex vivo cancerous and non-cancerous omentum tissue. An image of the working 
laboratory measurement set up is displayed in Fig. 1a. The larger magnification image shows the tungsten work-
ing electrode inserted into a non-cancerous omentum tissue, both the tissue with tungsten electrode and Ag|AgCl 
reference electrode are partly submerged in the same media solution, and a measurement is recorded on Labchart 
software. Figure 1b illustrates in detail the methodology developed14,15 and the main components of our tissue 
measurement system for recording tissue biopotential measurements. The biopotential present between a tung-
sten electrode which pierces the human tissue sample and a Ag|AgCl reference electrode is recorded by means of 
appropriate interfacing circuitry whose output is processed by a commercially available data acquisition system 
and is subsequently visualised onto a computer screen. Both the tissue sample and the reference electrode are in 
contact with cell culture media solution with the tip of the tungsten electrode piercing the tissue sample without 
making contact with the media solution. Sub-panels (A)-(D) of Fig. 1b offer functional block representations of 
the main components constituting our measurement method.
The resting biopotential was measured in triplicate in different regions of paired macroscopically 
non-cancerous and cancerous omentum tissues excised from patients undergoing maximal effort primary 
cytoreductive surgery for advanced epithelial ovarian cancer (n = 36). We consistently observed a significantly 
lower biopotential measurement in the cancerous tissue compared to the paired non-cancerous tissue (Fig. 2a, 
p < 0.001). The trend of lower cancerous biopotential values versus non-cancerous readings was consistent in all 
paired tissues, over all cases, despite a large range of biopotential values recorded (Fig. 2b, p < 0.001). Additionally, 
to determine whether the size of the tissue measured had any influence on biopotential levels, excised cancerous 
tissue samples were measured for biopotential, and dissected into smaller sizes (width or depth) while retaining 
the working tungsten electrode in the same position within the tissues to record biopotential following each 
dissection. No change in biopotential was observed in any of the tissues dissected (Supplementary Figure S1).
Biopotential levels associate with tissue cellularity. Immunohistochemistry for the tumour mark-
ers Pax8 and WT1, commonly associated with EOC and HGSOC18, was performed to determine the tumour 
cell load in tissues and demonstrated the presence of micro-metastasis of tumour cells in some of the macro-
scopically non-cancerous tissues measured (Supplementary Figure S2). Biopotential readings were correlated 
with a tumour, stromal and adipose tissue score for the cancerous tissues (Fig. 3) and non-cancerous tissues 
(Supplementary Figure S3). For the cancerous tissue, a positive correlation between increasing tumour load and 
biopotential, and a negative association between higher biopotential levels and the amount of stroma present was 
detected. When stratifying at median biopotential levels for the cancerous tissues, we observed biopotential levels 
above the median biopotential associated with higher tumour content in the tumour tissues (Fig. 3a) and bio-
potential levels below the median associated with a higher percentage of stroma in the tumour tissues (Fig. 3b), 
with a similar trend observed between lower biopotential levels and adipocyte content in the tumour tissues 
(Fig. 3c). Little correlation was observed between tumour, stroma and adipocyte content in the macroscopically 
non-cancerous tissues (Supplementary Figure S3).
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Figure 1. Laboratory set up for recording of biopotential readings. (a) Experimental laboratory set up for 
recording of biopotential measurements in a sterile laminar flow cabinet, measurements are recorded using 
Labchart software on a laptop set up outside the laminar flow cabinet. Inset shows the tungsten working 
electrode inserted in a piece of non-cancerous omentum tissue and partly submerged in media. The Ag|AgCl 
reference electrode is also placed in a 1 ml pipette tip which is partly submerged in the same media beaker. (b) 
Developed methodology for recording of tissue biopotential readings. The analog voltage difference, present 
between a tungsten electrode that pierces the human tissue and a Ag|AgCl reference electrode submerged in 
cell culture medium solution, is recorded by means of an interfacing circuitry. The output of the interfacing 
circuitry is processed by a commercially available data acquisition system (Powerlab data acquisition hardware) 
and is depicted on the computer screen. (A) Detailed view of the electrochemical cell. Both the Ag|AgCl 
reference electrode and the tissue sample are in contact with cell culture medium solution. The tip of the 
tungsten electrode (dashed line) pierces the cancerous/non-cancerous tissue sample but does not make contact 
with the medium solution. This ensures that the voltage measurement is taken from the tissue sample and not 
from the medium solution. (B) Detailed view of the interfacing circuitry. It consists of a high-performance 
instrumentation amplifier (INA), which amplifies the voltage difference between the tungsten and the Ag|AgCl 
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Furthermore, to establish if cell density influenced biopotential levels, we suspended increasing numbers of 
immortalised cells (SKOV3) in a 3D collagen matrix model in vitro and measured the biopotential of each 3D 
model. We observed decreasing levels of biopotential in the collagen matrix modified with increasing numbers 
of cells (Supplementary Figure S4a). Moreover, using different densities of agarose as an in vitro tissue surro-
gate to examine the influence of matrix (tissue) stiffness on biopotential, we determined that biopotential levels 
decreased in a series of gel matrices with increasing density (Supplementary Figure S4b). Thus, showing that 
biopotential levels can be influenced by cell type, cell number and matrix stiffness.
Biopotential levels in omentum tumours associate with late stage and poor clinical out-
come. All biopotential measurements were correlated with the clinical details and outcome of each patient 
(Table 1). We observed a significant correlation of high biopotential readings in the cancerous omentum tissues 
associated with advanced tumour stage (Fig. 4a, p = 0.04873). Furthermore, we examined whether there was any 
correlation of biopotential levels measured in the cancerous tissues with progression-free survival (PFS) for the 
entire cohort of patients (Fig. 4b) and for patients with only the HGSOC subtype (Fig. 4c). When biopotential lev-
els are stratified at the median normalised cancerous biopotential, biopotential levels below the median were asso-
ciated with a poorer PFS for all EOC histotypes and HGSOC only cases (p = 0.0179 and p = 0.0143 respectively).
Changes in tissue biopotential levels correlate with apoptosis pathways. Reverse phase protein 
array (RPPA) proteomic profiling was performed on paired non-cancerous and cancerous tissues from 10 patients 
with HGSOC within our cohort to assess the effect of differing tissue biopotential levels on protein signalling. 
These patients were selected based on the extreme differences in biopotential recorded between their cancer-
ous and non-cancerous tissues. Common pathways that were statistically significant following linear regression 
analysis were apoptosis related pathways (Table 2). When analysing correlation statistics in biopotential changes 
between non-cancerous and cancerous samples and protein expression, the cell cycle protein CDK1 was the only 
statistically significantly altered protein observed (Table 3).
From the RPPA data of the paired HGSOC tissue samples, further linear regression analysis was performed to 
identify any associations in protein expression changes between paired samples and patient outcome. A number 
of proteins were identified to be statistically significantly altered (Supplementary Table S1). Only lactate dehy-
drogenase A (LDHA) showed a clear differential expression related to patient outcome, with high levels of LDHA 
at the onset of the disease being associated with a significantly higher risk of future relapse and poor outcome 
(Supplementary Figure S5).
Lower biopotential is associated with increased lactate/glucose ratio. As cancerous cells often 
exhibit anaerobic metabolism, in some of our paired ex vivo omentum samples dialysate levels of glucose and 
lactate were measured at the same time as the biopotential was measured. The levels of these metabolites and the 
corresponding lactate/glucose ratio, which is often found to be a more sensitive marker than either metabolite 
alone19, for these paired omentum samples are shown in Fig. 5b. The results indicate that cancerous omentum has 
significantly higher lactate levels than its paired non-cancerous appearing tissue (p < 0.05). This is also reflected 
in the lactate/glucose ratio, which is significantly higher in cancerous omentum (p < 0.01).
Discussion
Our study demonstrates, for the first time, a significant predictive value of the bioelectrical properties of cancer-
ous tissue for higher risk of recurrence, poor clinical outcome as well as advanced stage in patients with epithelial 
ovarian cancer. In an era where ground-breaking novel bioengineering advances are finding their way into many 
aspects of medical care, current bioengineering advances have focused on rapid diagnostics and identification of 
tumour margins such as the iKnife20, the MasSpec Pen21, and fiber pH probe22. In this study, we have established a 
novel bioengineering approach which could reliably inform on patients’ clinical and surgical outcome and guide 
surgical decision-making, as well as distinguishing between cancerous and non-cancerous tissue. Especially in 
cancer surgery, the development of validated algorithms that could guide personalised surgical and clinical man-
agement is warranted in an effort towards a more individualised care approach. From our approach profiling the 
bioelectrical and metabolic properties of cancer tissue correlated with validated biomarkers of outcome, there is a 
potential opportunity to use this information to develop a pre-operative algorithm that could help tailor surgical 
radicality directing an ultra-radical approach to patients that will benefit most. Thus, sparing those patients who 
will fail radical treatment and subsequently relapse early, an unnecessary surgical morbidity and direct them 
towards alternative therapeutic principles.
From a biomedical engineering standpoint, we have demonstrated that it is possible: (a) to conceive novel 
methods to measure precisely biophysical properties (tissue biopotential) and (b) engineer biochemical tissue 
signature (energy metabolites) measurement methods even in the difficult circumstances of excised tissue from 
an ongoing operation. To achieve this, it was necessary to develop novel sampling probes and controlling circuitry 
double junction reference electrode, and an operational amplifier (OPA) connected as a voltage follower, which 
acts as a buffering stage between the interfacing circuitry and the following stage (Powerlab data acquisition 
hardware). (C) Detailed view of the commercially available Powerlab data acquisition hardware. The amplified 
signal coming from the interfacing circuitry is low-pass filtered (LPF) with the cut-off frequency set at 10 Hz. 
Next, the filtered signal is digitized by a 16-bit analog-to-digital converter (ADC). (D) The digital signal is 
depicted on the computer screen using the graphical user interface (GUI) offered by the Powerlab system 
(Labchart).
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and then translate them to a clinical environment. We have shown that our measurement devices are practical and 
produce results with potential clinical value.
We observed consistent significantly different biopotential values in the cancerous tissue compared to the 
paired non-cancerous tissue; this was the case in all patients analysed. In an effort to identify what factors could 
influence bioelectrical properties, we demonstrated that biopotential measurements are influenced by matrix 
stiffness and cell density using in vitro agarose and 3D collagen models. Several studies have demonstrated that 
extra-cellular matrix stiffening promotes the progression of many cancers23, and a recent study examining the 
evolving tumour microenviroment of EOC omental metastasis suggests a close association of tissue matrix stiff-
ness with disease progression24. In the follow-up validation of our current feasibility study we will aim to correlate 
tissue biopotential measurements with corresponding tissue stiffness measurements, to confirm the relation-
ship between matrix stiffness and biopotential. We identified a positive correlation between increasing tumour 
load and biopotential levels in cancerous tissues, and a negative association between low biopotential levels and 
increasing amount of stromal tissue present. The role of the stromal compartment in tumours has been shown to 
be indicative of a poorer outcome in cancers including EOC25,26. Moreover, the size of sample or tissue measured 
did not influence subsequent biopotential readings, demonstrating that the tungsten measurement electrode only 
detected the biopotential signal in its immediate vicinity.
In relation to clinical parameters, we could demonstrate a significant correlation between biopotential levels of 
cancerous omentum with tumour stage and clinical outcome. High biopotential levels in the cancerous omentum 
were significantly associated with advanced stage IV tumour. Furthermore, when stratifying at median biopoten-
tial over all the omental tumours assessed, levels below the median were associated with a poorer progression-free 
survival for all EOC histological subtypes, and the most prevalent HGSOC subtype also. Proteomic analysis of a 
subset of HGSOC cases in our cohort revealed the most common pathways associated with changes in biopoten-
tial between cancerous and non-cancerous tissues were apoptosis related pathways, and altered CDK1 expression 
significantly correlated with changes in biopotential. It is known that deregulation of pro- and anti-apoptotic 
pathways is a key factor in the onset and maintenance of chemotherapy resistance in ovarian cancer, and many 
genes involved in apoptosis are aberrantly regulated in ovarian cancer. Overexpression of CDK1 has been associ-
ated with several cancers, in particular in EOC increased expression of CDK1 correlated with poor prognosis27,28, 
and may also be a valuable biomarker for EOC to incorporate into a potential prognostic algorithm.
There was also a clear positive clinical correlation in the proteomic analysis of the paired HGS cancerous 
versus non-cancerous samples with increased LDHA expression being associated with a significantly higher 
risk of future relapse and poor outcome. One of the most fundamental steps in the process of aerobic glycoly-
sis is the conversion of pyruvate to lactate in cytosol by the NADH-dependent enzyme, lactate dehydrogenase 
(LDH)29. LDHA overexpression has also been observed in different cancer types including ovarian cancer sub-
types and shown to be a potential feedback activator of hypoxia inducible factor in ovarian cancer cell lines30,31. 
Furthermore, our metabolic profiling for lactate and glucose levels demonstrated that higher lactate and lower 
glucose levels coincided with lower biopotential readings in the cancerous tissue compared with the paired 
non-cancerous appearing tissue. This is likely due to the inherently hypoxic tumour environment leading to 
elevated levels of lactate in cancerous tissue but also due to the higher energy consumption and hence glucose 
consumption by the cancerous tissue. These preliminary metabolite results are promising and suggest that levels 
of metabolites along with potential tumour biomarkers such as LDHA could contribute to a panel of markers that 
could provide insight into tumour biology, associated with corresponding biopotential profiles.
Figure 2. Biopotential levels differ between paired cancerous and non-cancerous tissues. (a) Biopotential data 
captured in the laboratory 45–120 min post removal on excised, paired omentum samples with macroscopically 
non-cancerous and cancerous appearance in different areas of the tissues. All biopotential readings were 
measured in triplicate and normalized to a reference media reading. Across the patient series, lower biopotential 
readings were observed for all cancerous samples compared to its paired non-cancerous counterpart (p < 0.001, 
n = 36). (b) A range of biopotential readings were collected across the patient series (each dot represents the 
mean of each tissue’s biopotential) for all tissues collected, consistently cancerous tissue had a lower biopotential 
than its non-cancerous pair (p < 0.001, n = 36).
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This type of approach and deployment of bioengineering principles and techniques in ovarian cancer sur-
gery is unique. For that reason, we had to adapt currently available bioengineering tools to the measurements of 
omentum tissue following dissection from oncologic cytoreductive surgeries and develop new techniques and 
principles. We have intentionally chosen a tungsten working electrode for the biopotential measurements because 
of its properties; it is hard, chemically inert, does not oxidize or corrode easily, and is resistant to attack from acids 
and alkalis32, rendering it ideal for voltage measurements in tissue samples. A double junction Ag|AgCl reference 
electrode was preferred to avoid contamination of the results by junction potentials, the relative convenience of 
manufacturing, its high reproducibility and the good stability of its potential33. A high-performance instrumen-
tation amplifier was preferred because it removes the common-mode noise from the input signal. Thus, the out-
put amplified signal was less susceptible to noise. Another advantage of using an instrumentation amplifier was 
that it offers a very high differential mode input impedance for efficient interfacing with the reference electrode. 
The metabolic measurements were more challenging; even though the microdialysis sampling has allowed us to 
gather preliminary metabolite data from human tissue samples, in some cases it was technically very difficult to 
obtain reliable measurements from non-cancerous omentum tissue as the tissue was very thin and compliant, 
Figure 3. Potential biological correlations with biopotential readings in advanced ovarian cancer. Three 
different sites in the cancerous omentum from ten EOC cases were analysed. (a) Box plot representing 
the positive correlation between tumour content and biopotential levels, stratified at normalized median 
biopotential levels into low (below the median) versus high (above the median). High biopotential levels 
significantly correlated with increased tumour load (p = 0.0355) (b) Box plot showing that increased stromal 
content negatively correlates with low biopotential. (c) Adipocytes content and biopotential showed a trend 
with increased adipocyte load correlating with low biopotential. The correlations were measured by Spearman’s 
correlation coefficient and t-test.
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leading to issues inserting the probe completely without damaging the membrane. These dialysate metabolite 
readings obtained have provided us with a range of expected metabolite levels in cancerous and non-cancerous 
tissue, guiding future biosensor development.
Our approach, while still in its preliminary stages and relying on bioengineering principles not applied in this 
manner previously, has potentially transformative implications on clinical practice. Our next aim is to validate 
these findings in a large prospective cohort, to ascertain the feasibility that clinicians could use the bioelectrical 
properties of cancerous tissue to reliably predict outcome of their patients and hence tailor their treatment and 
individualise intended radicality. Furthermore, in an effort to make the actual tissue measurements less challeng-
ing and more user friendly for clinicians, we are in the process of developing a microprobe pen-like device which 
will miniaturise and incorporate the technology presented here to detect biopotential and metabolites in real time 
and hence be able to generate in the theatre a signature predictive of outcome either in vivo or ex vivo after tumour 
excision or even from a biopsy of cancerous tissue. On the basis of the biopotential signature obtained, clinicians 
would be able to allocate patients towards a standard versus ultra-radical surgical approach, performing the latter 
only on those who will have a true survival benefit when balanced with the resultant iatrogenic morbidity. This 
research approach will significantly contribute towards personalising surgical care, a large area of highly unmet 
need for patients with advanced EOC, while presenting innovative bioengineering technology which could be 
applied to other cancer types in the future.
Methods
Intra-operative collection of patient samples and clinical follow up. At the time of cytoreductive 
surgery for advanced primary EOC, macroscopically cancerous omentum and paired macroscopically non-can-
cerous omentum tissues were collected and immediately transferred to the laboratory for ex vivo biopotential 
measurements and further analysis. All surgical and clinical patient and tumour related data were prospectively 
collected (Table 1). The project was performed under the Hammersmith and Queen Charlotte’s and Chelsea 
Research Ethics Committee approval 05/QO406/178, and supplied by the Imperial College Healthcare NHS Trust 
Tissue Bank, following full informed patient consent. All methods were performed in accordance with the rele-
vant guidelines and regulations. Inclusion criteria for our study comprised patients undergoing primary maximal 
effort cytoreductive surgery for advanced EOC, FIGO stage III-IV, chemotherapy-naïve, with no previous malig-
nancies. Patient samples were exclusion from the study if the patients had received neo-adjuvant chemotherapy, 
or were non-EOC or non-ovarian histotype.
Patients were regularly evaluated at the end of their surgical and systemic treatment for evidence of disease 
recurrence. Clinical history, examination and CA-125 (if the pre-operative value was elevated) were performed 
every 3 months for the first 2 years and then 6-monthly. A CT/MRI-scan was ordered if the above examinations 
revealed any pathology. Isolated CA-125 elevation was not regarded as a recurrence.
Biopotential measurement collection. Paired macroscopically-appearing cancerous and non-cancerous 
omentum tissues of all evaluated patients were assessed for their bioelectrical properties. Biopotential was 
Patient information N = 36
Patient age
   Median 64
   Range 32–84
Death
   No 31
   Yes 5
Recurrence
   No 22
   Yes 11
Histology
   Low grade serous 2
   High grade serous 32
   Clear cell 2
FIGO Stage
   III 18
   IV 18
Residual disease
   Tumour free 31
   <0.5 cm 4
   >0.5 cm 0
   1-2 cm 0
   >2 cm 1
Table 1. Clinical and histological details of all patients enrolled in the study (n = 36).
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measured using an experimental setup comprised of an electrochemical cell consisting of two half cells, a tung-
sten working electrode, a silver-silver chloride (Ag|AgCl) double junction reference electrode, an instrumentation 
amplifier, an RPMI 1640 cell culture medium (Life Technologies, Carlsbad, CA), and one ml pipette tips. The 
electrode (UEWSHGSE3N1M from FHC) is made up of two regions (Supplementary Figure S6b). The first region 
is the tungsten material, which is fully insulated with epoxylite insulation. The shank diameter of this region is 
500 µm. Only the final tip, which is 120 µm in length with a diameter of less than 1 µm, is exposed (conductive) to 
be able to take voltage measurements. The final taper angle is 10°−15°. The second region (gold part) is conduc-
tive and is used to connect the electrode with the electronic equipment.
As illustrated in Fig. 1b, the tissue sample is placed in a pipette tip, partly immersed in media in a beaker. 
The bottom of the pipette tip is open so that the tissue is in direct contact with the media. The tip of the tungsten 
electrode pierces the surface of the tissue without making contact with the media. This ensures that the voltage 
difference measurement is taken from the interior of the tissue sample only. The Ag|AgCl electrode is also placed 
Figure 4. Biopotential readings correlate with tumour stage and poor progression free survival. (a) 
Biopotential readings of all advanced ovarian cancer cases at Stage III (n = 18) and Stage IV (n = 18) shows 
that higher biopotential levels associate with late stage. The p-value was determined by Welch two Sample t-test 
(p = 0.0487). (b) Kaplan-Meier plot representing the biopotential association with PFS in ovarian cancer cases 
of all subtypes (n = 31). (c) Biopotential association with PFS in high grade serous ovarian cancer (n = 27). In 
both Kaplan-Meier analysis, the patients were dichotomised at median biopotential and formed the biopotential 
high group (red) and the biopotential low group (blue). Within the cohort of patients with biopotential below 
the median, it was a 2:1 ratio of patients with Stage III versus Stage IV EOC disease. The p-value was given by 
log-rank test. Additionally, hazard ratio (HR), 95% confidence interval and the corresponding p-value was given 
by Cox regression.
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in media inside a second pipette tip forming a double-junction reference electrode immersed in the media in the 
beaker. A double-junction reference electrode was preferred because it allows the chloride (Cl−) contained in the 
Ag|AgCl reference electrode to slowly mix with the media in the pipette tip and not with the tissue. This prevents 
contamination of the tissue by chloride and contamination of the Ag|AgCl reference electrode by the blood/liquid 
coming from the tissue. Fresh media is used in each experiment.
The negative and positive terminals of the instrumentation amplifier were connected to the Ag|AgCl ref-
erence electrode and the tungsten electrode, respectively. The instrumentation amplifier recorded and ampli-
fied the potential difference between the two electrodes, while the electrochemical cell had to be in equilibrium 
before taking biopotential measurements. The output of the instrumentation amplifier was connected to a data 
acquisition system (PowerLab, ADInstruments), which converted the analogue output from the instrumentation 
amplifier into a digital signal. This signal was visualized on a computer for further analysis. More details on the 
adapted method can be found in14. The biopotential of each tissue sample was measured over a 2-minute period 
per measurement in 3 different areas of each tissue collected, and data was normalised to the reference media 
biopotential measurement.
Determination of tumour cellularity. In order to associate biopotential levels with tumour and stromal 
cellularity following biopotential measurement, measured tissue pieces were retained for histological assessment 
using common ovarian cancer tumour markers and determination of a tumour cellularity score. Following col-
lection of biopotential and metabolite dialysate, tissue samples were snap frozen and stored at −80 °C prior to 
histological processing. Tissue samples were sectioned using a Bright Cryomicrotome and 10 µm sections were 
collected. Haematoxylin and eosin staining was carried out for each sample. For tumour and stroma confirma-
tion, a selection of tumour (Pax8 – Abcam cat. no. 189249 and WT1 – Abcam cat. no 89901) and mesothelial 
Pathway Identifier P Value Adjusted P Value
Intrinsic Pathway for Apoptosis 9.8E-07 0.0011
Activation of BH3-only proteins 2.4E-05 0.014
Programmed Cell Death 6.6E-05 0.017
Apoptotic signaling in response to DNA damage 8.0E-05 0.017
Apoptosis 9.0E-05 0.017
Activation of BAD and translocation to mitochondria 1.1E-04 0.017
TCF dependent signaling in response to WNT 1.2E-04 0.017
Glucagon signaling pathway - Homo sapiens (human) 1.9E-04 0.024
Metformin Pathway, Pharmacodynamic 3.8E-04 0.039
TNF alpha Signaling Pathway 4.0E-04 0.039
TWEAK Signaling Pathway 4.1E-04 0.039
Corticotropin-releasing hormone 4.6E-04 0.040
Table 2. Pathway analysis of the log-fold change in protein expression changes with normalised biopotential 
changes. Pathway enrichment analysis was performed to determine pathways that are significantly altered 
when comparing protein expression changes between cancerous and non-cancerous samples and biopotential. 
Correlations between these factors were ranked upon the gradient of the trend observed. All significantly 
enriched pathways are shown, with apoptosis related pathways being frequently represented.
Protein Probe logFC P Value Adjusted P Value
CDK1 10.08 9.3E-05 0.028
INPP4b −2.08 6.7E-04 0.064
FAK pY397 −2.85 8.7E-04 0.064
PKM2 9.05 1.1E-03 0.064
EMA 12.70 1.2E-03 0.064
PAICS 2.93 1.9E-03 0.064
CD31 −2.79 1.9E-03 0.064
Bcl xL 4.25 2.2E-03 0.064
Bcl2 −3.18 2.3E-03 0.064
S6 pS235 S236 6.25 2.6E-03 0.064
Table 3. Change in normalised biopotential vs protein log fold change between cancerous and non-cancerous 
samples. Correlation statistics between changes in biopotential and protein expression between cancerous and 
non-cancerous samples, respectively (n = 10). The tumour cellularity difference between cancerous and non-
cancerous samples are also included in this model. Linear regression analysis was performed to generate these 
statistics, including the log2 fold change (logFC) of the trend observed, the p-statistic and adjusted p-statistic. 
Top 10 most significant trends are shown, with CDK1 being the only statistically significant observation.
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cell markers (Calretinin – Dako, cat. no M7245) were used. All sections were fixed with 4% PFA (ChemCruz, 
sc-281692) for 10 minutes at room temperature (RT) and washed 3 times, every 5 minutes with 1x tris buffered 
saline (TBS). Pax8 staining required an additional step of antigen retrieval with 10 mM sodium citrate buffer 
pH8.5 for 40 minutes. All sections were treated with an endogenous peroxidase blocking solution (70% methanol, 
28% deionized water and 2% hydrogen peroxide) for 5 minutes, washed 3 × 5 minutes with 1x TBS and blocked/
permeabilised with a solution of 6% goat serum and 0.5% Triton X-100 in 1x TBS for 1 hour. Primary antibodies 
were incubated overnight at 4 °C at 1:50 Pax8, 1:200 WT-1, and 1:50 Calretinin, in 1x TBS with 6% goat serum 
and 0.1% Triton X-100. Sections were washed with 1x TBS 3 × 5 minutes, and incubated in the corresponding 
secondary antibodies: 1:200 biotinylated anti-rabbit IgG (Vector lab BA-1000) or biotinylated anti-mouse IgG 
(Vector lab BA-9200) for 30 minutes at RT. Sections were washed with 1x TBS and the avidin-biotin complex was 
developed with the Vectastain ABC kit (Vector lab PK-6100) for 30 minutes at RT, followed by 1x PBS for 5 min-
utes. Peroxidase substrate (ImmPACT DAB Peroxidase substrate, Vector Lab SK-4105) was added for 30 sec-
onds for sections stained with WT1 and Calretinin, and 40 seconds for sections stained with Pax8. All sections 
were counterstained with haematoxylin (LAMB, 230-D) and mounted in DPX (Sigma, 06522). All sections were 
scanned using a Zeiss AxioScan Z1. The images obtained were analyzed with QuPath software34 to determine the 
tumour cellularity of each tissue sample measured for biopotential and metabolites.
Tumour protein lysate preparation. Ten frozen 30 µm sections of tissue were collected by cryotomy 
from two paired cancerous and non-cancerous omentum tissues from 10 cases from our sample cohort, all 
high grade serous ovarian cancer (HGSOC), and mechanically lysed in cold RPPA lysis buffer 1% Triton X-100, 
50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM Na4P2O7, 10% glycerol 
containing freshly added protease (Roche Applied Science, 05056489001) and phosphatase inhibitors (VWR, 
524625)), lysates were incubated on ice for 30 minutes and centrifuged at 14000 rpm for 10 minutes at 4 °C. The 
supernatants were retained and stored at −80 °C. Protein concentrations were determined by BCA assay (Thermo 
Scientific). Lysates were shipped to the RPPA facility, MD Anderson Cancer Center, USA and analysed as previ-
ously described35.
Dialysate collection for metabolite measurement. In order to measure the metabolites of the tissues 
and correlate it with the biopotential measurements, two CMA 12 microdialysis probes (Linton Instruments, 
4 mm membrane length) were inserted into each sample of either cancerous or non-cancerous omentum tissue. 
The CMA probes were chosen because they were rigid, even so it was necessary to use a 21-gauge hypodermic 
needle to make a small hole in the tissue before inserting the smaller diameter microdialysis probe to avoid 
Figure 5. Laboratory setup for dialysate collection. (a) Two probes are inserted into non-cancerous tissue (left) 
and cancerous tissue (right) and perfused simultaneously using a syringe pump. The dialysate is collected in 
0.75 m lengths of collection tubing. (b) Box and whisker diagrams comparing dialysate glucose levels (red), 
lactate levels (green) and lactate/glucose ratio (black) for paired omentum tissue with low and high biopotential 
(n = 12). Statistics tested using two-tail Wilcoxon sign rank test.
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damage to the membrane. The probes were positioned close together and were perfused at 1 µl/min with T1 
perfusion solution (2.3 mM calcium chloride, 147 mM sodium chloride, 4 mM potassium chloride). The outlet 
of each probe was connected to a 0.75 m length of coiled Portex fine-bore storage tubing (0.4 mm inner diameter, 
Smiths Medical, UK)36 in a sterile tissue culture hood, as shown in Figure 5a. The storage tubing was primed with 
T1 solution and was labelled to record the direction of flow. After 30–40 min of dialysate collection, the sample 
tubes were sealed to avoid losing the sample and frozen until analysis for levels of glucose and lactate using the 
microfluidic biosensor system.
Microfluidic biosensor system. To analyse each sample, the stored dialysate was pumped through the 
analysis system, effectively ‘replaying’ the liquid stream as if it were flowing in real time. Our custom-built micro-
fluidic biosensor system has been described previously16,17. Briefly, glucose and lactate biosensors were fabricated 
using combined needle electrodes37 and functionalized in three layers38,39 and were positioned in a poly(dimethyl-
siloxane) (PDMS) microfluidic chip40. The thickness of the outer diffusion-limiting layer can be varied to control 
the operational range and sensitivity of the biosensors.
Statistical analysis. All statistical analysis was done using R 3.3.1. For all analysis, three raw biopotential 
readings were measured and were normalized to the reference media control. The average value of the three rep-
licates was then calculated and referred below as biopotential readings or biopotential. Differential biopotential 
by stage was compared by two sample t-test with unequal variances. Survival analysis including the Kaplan-Meier 
plots and Cox regression was performed using ‘survival’ package. Log-rank test was applied to compare the sur-
vival distribution of the two patient groups split at median biopotential readings. Cox regression of the dichot-
omized patient groups with progression-free survival was performed to confirm the result of the log-rank test. 
Correlation between tumour, stromal or adipose content with biopotential was measured by Spearman’s correla-
tion coefficient (r) and t-test.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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